Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

ABSTRACT:

Introduction

Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating disease of the CNS and results in neurological disability. Existing immunomodulatory and immunosuppressive approaches lower the number of relapses but do not cure or reverse existing deficits nor improve long-term disability in MS patients.

Areas covered

Monogenic antibodies were described as treatment options for MS, however the immunogenicity of mouse antibodies hampered the efficacy of potential therapeutics in humans. Availability of improved antibody production technologies resulted in a paradigm shift in MS treatment strategies. In this review, an overview of immunotherapies for MS that use conventional monoclonal antibodies reactive to immune system and their properties and mec

SUBMITTER: Wootla B 

PROVIDER: S-EPMC4913471 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature